Effect of Vitamine D3 for the patients whith chronic hepatitis C who recieved PEG-interferon alpha plus ribavirin: possible applicaition for database establishment.
Not Applicable
- Conditions
- chronic hepatitis C
- Registration Number
- JPRN-UMIN000003694
- Lead Sponsor
- Division of Gastroenterology, Tohoku Univerisity Graduate School of Medicine
- Brief Summary
1(OH) vitamin D3 could improve the sensitivity of Peg-IFN/RBV therapy on HCV-infected hepatocytes by reducing the IP-10 production from PBMCs and ISGs expression in the liver.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Any contraindication for (PEG) interferon, ribavirin, and Vitamine D3 suppliments.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method